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Background: Community acquired pneumonia (CAP) is a high incidence disease resulting in about 260,000
hospital admissions per year in Germany, more than myocardial infarction or stroke. Worldwide, CAP is the most
frequent infectious disease with high lethality ranging from 1.2 % in those 20–29 years old to over 10 % in patients
older than 70 years, even in industrial nations. CAP poses numerous medical challenges, which the PROGRESS
(Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis) network
aims to tackle: Operationalization of disease severity throughout the course of disease, outcome prediction for
hospitalized patients and prediction of transitions from uncomplicated CAP to severe CAP, and finally, to CAP with
sepsis and organ failure as a life-threatening condition. It is a major aim of PROGRESS to understand and predict
patient heterogeneity regarding outcome in the hospital and to develop novel treatment concepts.
Methods: PROGRESS was designed as a clinical, observational, multi-center study of patients with CAP requiring
hospitalization. More than 1600 patients selected for low burden of co-morbidities have been enrolled, aiming at a
total of 3000. Course of disease, along with therapy, was closely monitored by daily assessments and long-term
follow-up. Daily blood samples allow in depth molecular-genetic characterization of patients. We established a
well-organized workflow for sample logistics and a comprehensive data management system to collect and
manage data from more than 50 study centers in Germany and Austria. Samples are stored in a central biobank
and clinical data are stored in a central data base which also integrates all data from molecular assessments.
Discussion: With the PROGRESS study, we established a comprehensive data base of high quality clinical and
molecular data allowing investigation of pressing research questions regarding CAP. In-depth molecular
characterization will contribute to the discovery of disease mechanisms and establishment of diagnostic and
predictive biomarkers. A strength of PROGRESS is the focus on younger patients with low burden of co-morbidities,
allowing a more direct look at host biology with less confounding. As a resulting limitation, insights from
PROGRESS will require validation in representative patient cohorts to assess clinical utility.
Trial registration: The PROGRESS study was retrospectively registered on May 24th, 2016 with ClinicalTrials.gov:
NCT02782013
Keywords: Pneumonia, Sepsis, Prospective observational study, Disease progression, Biomarkers, Innate immunity,
Data base, Biobank* Correspondence: peter.ahnert@imise.uni-leipzig.de
†Equal contributors
1Institute for Medical Informatics, Statistics, and Epidemiology (IMISE),
Medical Faculty, University of Leipzig, Haertelstr. 16-18, 04107 Leipzig,
Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Ahnert et al. BMC Pulmonary Medicine  (2016) 16:108 Page 2 of 9Background
Community acquired pneumonia (CAP) is truly a high
incidence disease (5–10 cases/1000 inhabitants, up to 80
cases/1000 nursing home residents) which results in
about 260,000 hospital admissions per year in Germany
with an overall mortality for hospitalized CAP of about
13 % [2, 19, 35]. CAP is the most frequent infectious dis-
ease worldwide with high lethality [37]. Pneumonia in-
duced severe sepsis frequently jeopardizes successful
patient outcome in many medical situations [1]. Severe
sepsis and septic shock are the main causes of death on
non-coronary intensive care units [1, 4, 7]. According to
a recent study by Dremsizov et al., almost half of all pa-
tients with severe CAP developed sepsis in the PORT
study [6]. In Germany, the SepNet consortium has col-
lected important data on CAP as cause of sepsis in a
study of prevalence of severe sepsis and septic shock in
German Intensive Care Units (ICUs). In a prospective,
observational, cross-sectional study (454 randomly se-
lected ICUs in 310 hospitals in Germany, 3.877 patients
screened), respiratory tract infections were identified in
62.9 % of patients with severe sepsis; 39.1 % of infections
were considered as community acquired [7]. There is
clear evidence that in adults incidence of CAP requiring
hospitalization increases with age [2, 9]. Lethality shows
a similar pattern: AQUA-data reveal that lethality of
hospitalized CAP goes up from about 1.2 % in those 20–
29 years old to 12.3 % in the group 70–79 years old and
even 22.5 % in the group older than 90 years [2]. In con-
sequence, the health and economic impact of pneumo-
nia is substantial [35].
To date, substantial research efforts over many years
have illuminated the origin of CAP, its epidemiology and
potential new avenues for treatment [31]. Nevertheless,
major challenges remain: While several scoring systems
have been developed, their main strength lies in identify-
ing patients not requiring treatment in a hospital [18].
Assessment of disease severity still mainly relies on clin-
ical judgement and outcome prediction remains a chal-
lenge [3, 10, 21, 24]. The current lack of a validated
operationalization of disease severity throughout the
course of treatment in the hospital may hamper clinical
research [18].
To meet these challenges and to better understand
what determines individual immune responses to pneu-
monia we conduct a multi-centric observational study of
hospitalized patients with CAP in Germany and Austria
to establish a comprehensive database of high quality
clinical and molecular data. Data obtained will provide
the basis for clinical and molecular scoring systems help-
ing clinicians to decide which CAP patient can stay on a
regular ward and who is at high risk to progress to se-
vere pneumonia or even septic shock with necessity for
intensive care including artificial respiration. Thesystematic analytical discovery-driven approach chosen
will help to identify yet unknown targets and molecular
pathomechanisms in the complex dynamics of endothe-
lial barrier function during acute inflammation of the
lung [12, 22]. These may directly improve pneumonia
management (diagnostics, therapy) and contribute to a
better understanding of the pathophysiology of the
pneumonia-to-sepsis progression, which in turn will ac-
celerate the identification of new treatment options.
Current research supports the notion that broad as
well as in-depth molecular analyses may contribute to a
better understanding of disease mechanisms and also
lead to diagnostic and prognostic biomarkers [14, 29,
38]. Patients with and without infection may be distin-
guishable by e.g. gene expression profiles [5, 16, 28, 32].
Even causal pathogens may be detectable by analyzing
host biospecimen [25]. A strong association between
death from infection in adoptees and their biological,
but not adoptive parents suggested a genetic influence
on the risk for and outcome from infection [30]. More
recently, in the GenOSept study, analysis of data from
three cohorts suggested genetic variants associated with
survival from sepsis due to pneumonia [26]. It appears
worthwhile to study pneumonia systematically and to
collect clinical and concomitant molecular data as a
basis for further insights.
We here present the design of the PROGRESS
study which aims to provide new and in-depth clin-
ical and molecular data helping to elucidate variation
in host response to CAP. We hope to contribute to
the development of an operationalization of disease
severity, to the identification of clinical and bio-
markers of pneumonia progression in hospitalized pa-
tients, and to new therapeutic concepts. Here, we
describe clinical and molecular assessments of the
PROGRESS study to facilitate future co-operation and
complementary work related to the pressing research
questions in CAP.
Methods/Design
Study design and assessments
PROGRESS is a prospective multi-centric longitudinal
observational study on patients hospitalized due to con-
firmed CAP (Fig. 1). Biomaterials are collected for broad
molecular investigation. The study does not intend to in-
fluence treatment decisions; treatment is at the discre-
tion of the attending physician. PROGRESS is designed
to observe transitions from uncomplicated community
acquired pneumonia (uCAP) to severe CAP (sCAP) to
pneumogenic sepsis and septic shock (ssCAP). Patients
are enrolled within 48 h of hospitalization with CAP.
Routine clinical and laboratory data are collected for the
day of hospitalization, the day of enrolment (d0), and









































Fig. 1 Schematic view of the PROGRESS Study. Stars indicate the time periods or time points from which data originate. Data from study visits
correspond to the time range between the previous and current study visit. Patients must be enrolled within 48 h after hospitalization. Study
visits correspond to the time points when blood for biospecimen is drawn in the morning. If there would be less than 12 h between collection
of biospecimen at enrolment and at visit 1, visit 1 is postponed to the following morning
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ters for SOFA [33] and SIRS [27] are obtained daily on
d0 through d4, along with information on treatment
unit, respiratory support, medication, and newly ob-
served clinical and microbiological findings. Blood sam-
ples for molecular analyses are collected daily on d0
through d3. At hospital discharge, information like vital
status, number of days in intensive care or with respira-
tory support, and subsequent type of residence are docu-
mented. Patients are followed up regarding vital status,
quality of life (EQ-5D [15]), and new episodes of pneu-
monia at days 28, 180, and 360 after enrolment. Baseline
data comprise sociodemographic information, relevant
aspects of medical history, and treatment prior to
hospitalization.
Study population
PROGRESS aims at recruiting a total of 3000 CAP pa-
tients of different degrees of initial disease severity (see
inclusion criteria). As PROGRESS aims to provide data
on host parameters modulating the response to infection
in patients whose immune system appears clinically
uncompromised, several exclusion criteria apply (see ex-
clusion criteria). PROGRESS enrolls adult male and fe-
male patients from all ethnic backgrounds.Inclusion criteria
Study participants must be 18 years of age or older and
hospitalized within the past 48 h due to CAP confirmed
by a new pulmonary infiltrate on chest radiograph and
more than one of the following signs and symptoms of
lower respiratory tract infection: 1) Fever, 2) cough, 3)
purulent sputum, 4) shortness of breath or need for re-
spiratory support, or 5) crackling or rales on ausculta-
tion, dullness to percussion, or bronchial breathing.
Exclusion criteria
To ensure that the diagnosed pneumonia has not been
contracted in a hospital and to avoid patients whose im-
mune system may have been substantially compromised
for other reasons, the following exclusion criteria are ap-
plied: Patients must not have been hospitalized for any
reason within 28 days prior to hospitalization for the
current episode of CAP. Patients cannot be enrolled
with known HIV infection or AIDS or immunosuppres-
sive treatments within the past six months including
anti-tumor treatment, non-steroidal immunosuppressive
therapy, radiation therapy, or therapy with corticoste-
roids ≥ 20 mg for ≥ 14 days. Further exclusion criteria
comprise poststenotic pneumonia in conjunction with
bronchial carcinoma, organ or bone marrow transplant,
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brosis, active tuberculosis, acute lung injury or acute re-
spiratory distress syndrome for extrapulmonary reasons,
massive aspiration, sepsis with extrapulmonary focus,
acute pulmonary embolism, congestive heart failure
NYHA-IV, or liver insufficiency Child-Pugh C stadium.
Also, patients who are pregnant, breast feeding, previ-
ously participated in the PROGRESS study, or under
limitation of therapy are excluded from the study.
Study centers
Patients are recruited at study centers throughout
Germany and in Austria (Table 1), comprising emer-
gency wards and wards with normal, intermediate, or in-
tensive care. To qualify, a potential study center has to
regularly treat CAP patients, have capabilities to process
serum and plasma samples using a refrigerated centri-
fuge and store them at -20 °C, and have access to the
internet. To date, more than 50 study centers have con-
tributed over 1600 patients to PROGRESS.
Table 1 lists all study sites which so far con-
tributed patients to the PROGRESS study. Contact
to patients can be made through central study man-
agement (Petra Creutz: petra.creutz@charité.de or
Peter Ahnert: peter.ahnert@imise.uni-leipzig.de).
The study further remains open for participation by
interested hospitals. Before initiation of a study center,
study personnel have to undergo a comprehensive train-
ing program making them familiar with the aims of the
study, study procedures, electronic data entry, query
management, and sample processing and logistics.
Data collection and processing
In PROGRESS, study data are collected through stan-
dardized web-based data sheets (eCRF) into a central
database. PROGRESS aims to collect individual values
for all parameters of interest: Scores and derived values
are to be calculated centrally to avoid disparity in calcu-
lation procedures between study centers, increase oppor-
tunities for quality control, allow analysis of individual
parameters, and to empower development of new scores
and derivatives. Professional trial management and data-
base software are employed for remote data entry and
secure storage of clinical data, query management, and
basic reporting. Plausibility of data is checked directly
upon entry into the eCRF, by several hundred daily quer-
ies running on the central database, and in campaigns
performed by the data management and biometry teams.
Data management actively monitors resolution of identi-
fied problems, supported by clinicians from central study
management if necessary. Data regarding sample collec-
tion, processing, logistics, and from molecular measure-
ments in PROGRESS biospecimen are stored in the
same database, ensuring a high level of confidence insample identity and in matching biospecimen and data
from molecular measurements with patient data.
Ethics and data protection
Written informed consent for participation in the study
was obtained from all participants or, in case of critical
illness, from patient’s legal representatives. The study
protocol has been approved by the ethics committee of
the University of Jena (registration number 2403-10/08)
and all locally responsible ethics committees of all study
centers. The study protocol adheres to the requirements
of the Declaration of Helsinki [39] and to the ICH-GCP
guideline [8].
To achieve the objective of the study, it is necessary to
collect and process data and biospecimen of individual
patients. Identification of patients is possible only in the
study centers via a study specific patient pseudonym. All
inquiries of data management to the study centers as
part of quality assurance processes are using the pseudo-
nym. Collected biospecimen are identified by a ten-digit
code which is linked to the patient pseudonym at the
central database. Identification of specific patients is not
required at any time outside the study centers. To en-
sure that DNA samples cannot be linked to patient iden-
tity by anyone involved in the study and to also ensure
that DNA samples can be destroyed at patient’s request,
information linking DNA samples to patient identity are
held by an external data trustee.
Sample collection and biobanking
Specimen to be collected daily (days d0 through d3) in-
clude serum, EDTA plasma with protease inhibitors, cit-
rate plasma, and PAXgene blood for RNA. Samples are
collected, processed, and stored at -20 °C for up to three
months in the study centers. Samples are then shipped
to the Integrated Biobank Jena (IBBJ), the central bio-
bank of the PROGRESS network. A main goal was to
minimize the number of pre-analytical steps in study
centers to limit heterogeneity introduced by slight differ-
ences in personnel and procedures. Centralized and au-
tomated sample handling and processing helps to assure
standardization and to minimize sample loss and mix-
up, greatly contributing to high standards of quality. At
the biobank, sample aliquots are kept at -80 °C in a fully
automated sample store. Two vials of EDTA whole
blood for extraction of DNA are obtained from each pa-
tient and shipped directly to the biobank at ambient
temperature, then stored at -80 °C until processing.
Molecular assessments
Broad molecular analyses are an important focus of PRO-
GRESS. All study participants will be genotyped using the
CAP2 array, a customized array based on the Axiom plat-
form (Affymetrix). The CAP2 array comprises the
Table 1 Sites of Recruitment for the PROGRESS study
PROGRESS Study Site Location (City, Country, ZIP) Status
Krankenhaus Angermünde, Klinik f. Innere Medizin/Pneumologie Angermünde, Germany,
16278
Recruiting
Krankenhaus Bad Arolsen GmbH, Innere Medizin (Herz-, Kreislauf- u. Lungendiagnostik) Bad Arolsen, Germany, 34454 Recruiting
Hochtaunus-Kliniken, Medizinische Klinik III Bad Homburg, Germany,
61348
Recruiting
Lungenklinik Ballenstedt/Harz gGmbH, Ev. Fachkrankenhaus f. Lungenkrankheiten Ballenstedt, Germany, 06493 Recruiting
Vivantes Netzwerk f. Gesundheit GmbH Vivantes Klinikum Neukölln, Klinik f. Innere Med. - Pneumologie
u.Infektiologie - Thoraxzentrum
Berlin, Germany, 12351 Recruiting
HELIOS Klinikum Berlin-Buch, Interdisziplinäres Notfallzentrum mit Rettungsstelle Berlin, Germany, 13125 Recruiting
Charité - Universitätsmedizin Berlin, Medizinische Klinik m. S. Infektiologie und Pneumologie Berlin, Germany, 13353 Recruiting
Humboldt-Klinikum Vivantes, Kardiologie und kons. Intensivmedizin Berlin, Germany, 13509 Recruiting
Vivantes Klinikum Spandau, Kard., Pneum. und kons. Intensivmedizin Berlin, Germany, 13585 Recruiting
Gemeinschaftskrankenhaus Havelhöhe, Kardio-Pneumologie Berlin, Germany, 14089 Recruiting
Berufsgenossenschaftl. Universitätsklinikum Bergmannsheil GmbH, Klinik f. Pneumologie, Allergologie u.
Schlafmedizin
Bochum, Germany, 44789 Recruiting
Evangelische Kliniken Bonn, Betriebsstätte Johanniter Krankenhaus, Innere Medizin II Bonn, Germany, 53113 Recruiting
Med. Klinik d. Forschungszentrum Borstel, Fachkrankenhaus f. Lungenerkrankungen, Infektionen u.
Allergien
Borstel, Germany, 23845 Recruiting
Städt. Klinikum Dessau, Innere Medizin Dessau-Roßlau, Germany,
06847
Recruiting
Klinikum Dortmund gGmbH, Medizinische Klinik (Pneumologie/Infektiologie) Dortmund, Germany, 44145 Recruiting
Universitätsklinikum Carl Gustav Carus, TU Dresden, Medizinische Klinik 1 - Abteilung Pneumologie Dresden, Germany, 01307 Recruiting
SRH Wald-Klinikum Gera gGmbH, Medizinische Klinik 2 Gera, Germany, 07548 Recruiting
LKH-Univ. Klinikum Graz, UKIM Pulmologie Graz, Austria, 8036 Recruiting





Universitätsklinikum Hamburg Eppendorf, Onkologisches Zentrum, Pneumologische Studienzentrale Hamburg, Germany, 20246 Recruiting
Medizinische Hochschule Hannover, Klinik für Pneumologie Hannover, Germany, 30652 Recruiting
Klinkum Heidenheim, Medizinische Klinik II & Innere Intensiv Heidenheim, Germany,
89522
Recruiting
Kliniken d. Main-Taunus-Kreises, Klinik f. Pneumologie u. Allg. Innere Medizin Hofheim, Germany, 65719 Recruiting
Universitätsklinikum des Saarlandes, Innere Medizin V Homburg/Saar, Germany,
66421
Recruiting
Universitätsklinikum Jena, Klinik für Anästhesiologie und Intensivtherapie Jena, Germany, 07747 Recruiting
Universitätsklinikum Jena, Zentrum für Infektionsmedizin und Krankenhaushygiene, Studienabteilung Jena, Germany, 07747 Recruiting
Evangelisches Krankenhaus Kalk gGmbH, Innere Medizin/Pneumologie Köln, Germany, 51103 Recruiting
Universität Leipzig, Innere Medizin, Neurologie und Dermatologie, Pneumologie/Studiensekretariat Leipzig, Germany, 04103 Recruiting
Klinikum St. Georg gGmbH, Klinik für Infektions-/Tropenmedizin und Nephrologie Leipzig, Germany, 04129 Recruiting
Franziskus Krankenhaus Linz, Innere Abteilung Linz, Germany, 53545 Recruiting
Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Med. Klinik III (Pneumologie) Lübeck, Germany, 23538 Recruiting
Universitätsmedizin Mannheim, Studienkoordinierungszentrum, 1. Medizinische Klinik Mannheim, Germany, 68167 Recruiting
Städtisches Klinikum München GmbH - Klinikum Harlaching, Klinik für Gastroent., Pneum., intern. Akut- u.
Intensivmedizin
München, Germany, 81545 Recruiting
Krankenhaus München-Neuperlach, Klinik für Kardiologie, Pneumologie und Internistische Intensivmedizin München, Germany, 81737 Recruiting
Ev. Fachkrankenhaus für Atemwegserkrankungen Neustadt, Germany, 99762 Recruiting
Christliches Krankenhaus Quakenbrück e. V., Med. Klinik (Abtl. Pneumologie, Allergologie, Schlafmedizin) Quakenbrück, Germany,
49610
Recruiting
Mathias-Spital Rheine, Klinik für Pneumologie und Thoraxonkologie Rheine, Germany, 48431 Recruiting
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Diakoniekrankenhaus Rotenburg(Wümme)gGmbH, Zentrum für Pneumologie Rotenburg/Wümme,
Germany, 27356
Recruiting
Altmark-Klinikum gGmbH, Krankenhaus Salzwedel Salzwedel, Germany, 29410 Recruiting
Krankenhaus Bethanien gGmbH Solingen, Abt. Pneumologie Solingen, Germany, 42699 Recruiting
Universitätsklinikum Ulm, Klinik für Innere Medizin II, Sudienzentrale Innere II, Sektion Pneumologie Ulm, Germany, 89081 Recruiting
HELIOS Klinikum Wuppertal, Klinik für Intensivmedizin Wuppertal, Germany, 42283 Recruiting
HELIOS Klinikum Wuppertal, Pneumologie, Bergisches Lungenzentrum Wuppertal, Germany, 42283 Recruiting
Missionsärztliche Klinik GmbH Würzburg, Innere Medizin (Pneumologie) Würzburg, Germany, 97074 Recruiting
Universitätsklinikum Aachen, Med. Klinik I (Pneumologie) Aachen, Germany, 52057 Completed
Evangel. Krankenhausverein, Luisenhospital, Lungenzentrum Aachen, Germany, 52064 Completed
Evangelisches Krankenhaus Bad Dürkheim, Innere Medizin Bad Dürkheim, Germany,
67098
Completed
Knappschaftskrankenhaus Dortmund, Klinik für Pneumologie Dortmund, Germany, 44309 Completed
Uniklinikum Greifswald, Zentrum für Innere Medizin B Greifswald, Germany, 17489 Completed
Krankenhaus Martha-Maria Halle-Dölau, Klinik für Innere Medizin I Halle (Saale), Germany,
06120
Completed
ASKLEPIOS Klinik Wandsbek, 1. Medizinische Abteilung Hamburg, Germany, 22043 Completed
St.Vincentius-Kliniken gAG, Med. Klinik IV/Pneumologie Karlsruhe, Germany, 76137 Completed
Allgemeines Krankenhaus der Stadt Linz, Abteilung Lungenheilkunde Linz, Austria, 4021 Completed
St. Vincenz und Elisabeth Hospital Mainz, Innere Medizin Mainz, Germany, 55130 Completed
Dietrich-Bonhoeffer-Klinikum, Klinik f. Innere Medizin 2 (Abt. Pulmologie) Neubrandenburg, Germany,
17039
Completed
Pius-Hospital Oldenburg, Klinik f. Innere Med., Abt. f. Pneumologie Oldenburg, Germany, 26121 Completed
Brüderkrankenhaus St. Josef, Medizinische Klinik Paderborn, Germany, 33098 Completed
Universitätsklinikum Regensburg, Klinik Innere Medizin I, Intensivmedizin, Endokrinologie Regensburg, Germany, 93053 Completed
HELIOS Kliniken Schwerin GmbH, Klinik für Internistische und Neurologische Intensivmedizin/Stroke Unit Schwerin, Germany, 19049 Completed
Kreisklinik Trostberg, Innere Abteilung Trostberg, Germany, 83308 Completed
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array and about 60,000 custom SNPs. This custom
content consists of SNPs selected from existing litera-
ture evidence, eQTL data bases, GWAS data bases,
and data bases of functionally relevant mutations.
Genetic data from the CAP2 array are suitable for
imputation of genotype data with common genomic
references. Genome-wide gene-expression measure-
ments using the HumanHT-12v4 Expression BeadChip
(Illumina) comprise 47.000 transcript features in RNA
from stabilized whole blood (PAXgene Blood RNA
System, PreAnalytiX). Proteome analyses involve gel-
free LC-MS/MS focused measurements in EDTA
plasma samples stabilized by protease inhibitors (BD
P100 Blood Collection System for plasma protein
preservation, Becton Dickinson) and depleted for
highly abundant proteins. Collected biospecimen also
allow measurements of other serum and plasma pa-
rameters as well as cytokines. As patient samples are
available from consecutive study time points, time
series data can be established which are amenable to
temporal analysis of molecular response to infection.Discussion
PROGRESS collects clinical and molecular data for in-
vestigating the role of host factors modulating innate
immunity in patient’s response to community acquired
pneumonia. Most patients hospitalized with CAP re-
cover rather quickly while others will experience a se-
vere course of disease, with some requiring ICU
treatment including respiratory support. PROGRESS is
designed to investigate host factors beyond old age and
comorbidity which modulate the course of disease.
Therefore, PROGRESS was designed as a unique, de-
tailed, systematic, longitudinal study of CAP in Germany
and Austria focusing on the progression of hospitalized
community acquired pneumonia from mild CAP to very
severe disease including severe sepsis and septic shock.
Patients are closely followed for several days regarding
clinical and laboratory parameters and several biospeci-
men are collected on these days. Inspiration for the de-
sign of PROGRESS came from CAPNETZ and its study
on epidemiological and health research aspects of CAP
in Germany [34, 36]. Main differences of PROGRESS
compared to CAPNETZ are very stringent exclusion
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on hospitalized CAP, more comprehensive documenta-
tion on disease course within the first five days in the
hospital, and a stronger focus on molecular assessments.
Another inspiration for the PROGRESS study was the
“study on Genetic and Inflammatory Markers of Sepsis”
(GenIMS) in CAP in the US [17]. However, criteria in
PROGRESS are much stricter regarding exclusion of po-
tentially immunocompromised patients and options for
molecular assessments are broader. Inspiration regarding
the assessment of severely ill CAP patients came from
several SepNet [23] studies in Germany which, like the
European GenOSept study [13, 26], focus on patients
with sepsis of diverse origins, including pneumonia.
Stringent inclusion criteria ensure that only patients
with community acquired pneumonia are enrolled. A
new infiltrate in chest X-ray along with at least two
other clinical symptoms of pneumonia are required. Pa-
tients identified at later time points, or suffering from
tuberculosis or neoplasia of the lung, for instance, are
excluded from the study. To further ensure disease
homogeneity, patients who may have acquired pneumo-
nia in medical care facilities (hospital or health care ac-
quired pneumonia, HAP) or under respiratory support
(ventilator acquired pneumonia, VAP) are excluded. Nu-
merous exclusion criteria apply in an attempt to avoid
patients whose immune systems may be substantially
compromised by diseases with direct impact on the im-
mune system, other severe diseases likely to modulate
the course of pneumonia, or immunosuppressive treat-
ments. Along these lines, patients for whom a therapy
limitation is assumed are excluded. Decisions on limita-
tion of therapy that are made after enrolment are docu-
mented. Hence, patients enrolled in PROGRESS are not
representative of the overall population of hospitalized
CAP patients. Rather, PROGRESS patients will likely be
younger and generally healthier except for their acute
pneumonia. While our approach aims to get closer to
unconfounded biological heterogeneity regarding CAP
progression, this also requires that insights from PRO-
GRESS have to be validated in more representative pa-
tient cohorts before generalizations regarding all CAP
patients can be drawn.
By definition, it is impossible to observe patients hos-
pitalized with CAP without the influence of the hospital
environment. To come as close as possible to an analysis
of pure CAP, we require enrolment of patients within
48 h of hospitalization and are limiting detailed observa-
tion of patients to the first five to six days after arrival in
the hospital. At later time points, it cannot be ruled out
that hospital acquired infection may superimpose on the
initial CAP. However, major events and substantial
changes in patients’ health state are recorded until hos-
pital discharge to gain insight into the overall course ofdisease in the hospital. Patients are followed up by
telephone interview at days 28, 180, and 360 after
enrolment for vital status, recurrence of pneumonia,
housing situation, and quality of life. Thus, ques-
tions regarding long term consequences of CAP can
also be addressed.
In the PROGRESS study, microbiological data are
documented as they become available from routine
clinical materials, especially if materials were ob-
tained between hospital admission and day 4 of the
study. This includes culture from airway materials
and blood as a well as influenza rapid test and urine
antigen tests for legionella viruses and pneumococci.
Results from molecular techniques such as PCR are
also documented. Microbiological assessment will
likely be available for only a part of PROGRESS pa-
tients and disease causing agents will be detected
for only a fraction of patients. We hope to supple-
ment this information on disease causing agents in
the long run by molecular analyses of available bios-
pecimen. These analyses can be validated with docu-
mented microbiological data.
The main goal of PROGRESS is to contribute to the
improvement of clinical decision making and manage-
ment of patients with pneumonia and sepsis and of
therapeutic strategies. This will be achieved by clinical
and molecular investigation of host factors modulating
outcome of CAP and by identifying clinical scores and
molecular signatures for diagnosis, risk stratification,
prognosis, and outcome prediction.
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